{
 "PrintNo":"S3203","Session":2025,"Chamber":"SENATE","BillType":"Senate","Published":"2025-01-24T10:38:35.135011Z",
 "Status":"IN_SENATE_COMM","Committee":"Health",
 "Milestones":[{"Type":"IN_SENATE_COMM","Date":"2025-01-24","Committee":"Health"}],
 "Actions":[{"Text":"REFERRED TO HEALTH","Date":"2025-01-24","Chamber":"SENATE"}],
 "Sponsors":[
  {"ID":1520,"Name":"Nathalia Fernandez","Short":"FERNANDEZ"},{"ID":1500,"Name":"Samra Brouk","Short":"BROUK"},
  {"ID":1237,"Name":"Rachel May","Short":"MAY"},{"ID":1515,"Name":"Lea Webb","Short":"WEBB"}
 ],
 "Title":"Preserves access to affordable drugs",
 "Summary":"Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.",
 "LawSection":"Public Health Law","LawCode":"Add Art 2-A Title IV §§282 & 283, Pub Health L",
 "ActClause":"AN ACT to amend the public health law, in relation to preserving access to affordable drugs",
 "PreviousVersions":["S4370-2021","S4513-2023"]
}